Quebec agrees reimbursement of ABILIFY for schizophrenia treatment in public drug plans

Links shared publicly online about this topic.

771
total visits

Quebec agrees reimbursement of ABILIFY for schizophrenia treatment in public drug plans

Bristol-Myers Squibb Canada is pleased to announce that Quebec has recognized the value of ABILIFY (aripiprazole) for the treatment of schizophrenia and related psychotic disorders in adults and has agreed to list ABILIFY as a reimbursed full benefit on the Quebec public drug plans as of October 14, 2010.

View full resource at news-medical.net

Tags: Bipolar Disorder Medication, Schizophrenia, Schizophrenia Medication, Antipsychotic Medication, Psychotic Disorder, Drug, Abilify